Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
Trizivir
Philip Keiser, Naiel Nassar
Research output
:
Contribution to journal
›
Article
›
peer-review
3
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Trizivir'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Protease Inhibitors
100%
Human Immunodeficiency Virus Type 1 (HIV-1)
66%
Viral Replication
33%
Armamentarium
33%
Antiretroviral Therapy
33%
HIV Treatment
33%
Number of Patients
33%
Nucleoside Analogues
33%
Nucleosides
33%
Zidovudine
33%
Twice Daily
33%
Alternative Regimens
33%
Protease Inhibitor Therapy
33%
Lamivudine
33%
Indinavir
33%
Dosing Schedule
33%
Pill Burden
33%
Treatment of HIV Infection
33%
Abacavir
33%
Combination Tablet
33%
Plasma RNA
33%
Pharmacology, Toxicology and Pharmaceutical Science
Abacavir Plus Lamivudine Plus Zidovudine
100%
Proteinase Inhibitor
66%
HIV
50%
Human Immunodeficiency Virus Infection
16%
Side Effect
16%
Hyperlipidemia
16%
Nucleoside Analog
16%
Allergic Reaction
16%
Tablet
16%
Abacavir
16%
Nucleoside
16%
Indinavir
16%
Lamivudine Plus Zidovudine
16%
HIV Therapy
16%